DOCSLIB.ORG

Upregulated Glucose Metabolism Correlates Inversely with CD8 T Cell

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Upregulated Glucose Metabolism Correlates Inversely with CD8 T Cell Author Manuscript Published OnlineFirst on May 20, 2016; DOI: 10.1158/0008-5472.CAN-15-3121 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. V rtyhrq typr rhiyv p ryhr vr ry vu 89' U pryy vsvy hv hq vhy v h pryy ph pvh 8u vvh C Prrvr Fhr G Qr @yrh G Ch qr Ehh Thhxh Wr vxh Errv Eh Ayrvt Pyvr Xq Ertv X! 8u vur C Xryx! Bh ru E Uuh " Trur H Uuv qi tu " ! Svt vyr ! Fr q" #$ %$ !& Avhpvhy ' & ( )*+,-./,/0 8 rqvt hu & 1 " 1234+ ( 56678 ) *9++04:34;/<4: & 1= > Avt r hq hiyr< 1 * / 0?: & :! Downloaded from cancerres.aacrjournals.org on September 30, 2021. © 2016 American Association for Cancer Research. Author Manuscript Published OnlineFirst on May 20, 2016; DOI: 10.1158/0008-5472.CAN-15-3121 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 6i hp . & &> 1 > 1 @' > &> 1 ' 1 & 1 &A @ ' 1 ! 1 * #$0 B * 0 1 & 1 1 & & ' 1 C > #$& 1 1 &%( @#&' 1 & ' 4 Downloaded from cancerres.aacrjournals.org on September 30, 2021. © 2016 American Association for Cancer Research. Author Manuscript Published OnlineFirst on May 20, 2016; DOI: 10.1158/0008-5472.CAN-15-3121 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. D qpv & 1 $.!+ 28!-28!$ 1 *0 .& > 1 ! & ! 1 &> & 1 *0 & > &> 1 & &' 1 >& & 1 128!' D & 1 #$ 28!$*4:0 1 1 > &> > ! 1 ! &A E #$ B *+0 ' ' @2F! > B *@E 0 */0 . 3/G @2F! @E 1 ! 11 1 1 & > @2F! @E ' 1 #$ & & >> ! > 1 *60 *<0 :9 1 ! ! *3,0 & 1& ' 1 & #$ B' & 1 % . * %.0 1 ' 1 1 : Downloaded from cancerres.aacrjournals.org on September 30, 2021. © 2016 American Association for Cancer Research. Author Manuscript Published OnlineFirst on May 20, 2016; DOI: 10.1158/0008-5472.CAN-15-3121 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. ' > *C%E.0 *;0 E' > & ! ' ' 1 ! ' 1 1 1 &' ' C%E. 1 & 11 ' > '1 ' & 1 &' 1 ' ' >*0 1 #$ ' 1 1 1 1 1' & D @# 1 + Downloaded from cancerres.aacrjournals.org on September 30, 2021. © 2016 American Association for Cancer Research. Author Manuscript Published OnlineFirst on May 20, 2016; DOI: 10.1158/0008-5472.CAN-15-3121 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Hhr vhy hq Hruq WGCNA (' 1 1 > 1 1 ' %. 1(*40 D 1 !1 *:05 &A ' 1 ' > & *+0C%E.' ! 1C%E.>1 (*; /0 E' > ' 1 & 1 1 ' 1 % *--1 1-0 1 . 4 1 ' & 1 *% .0 1 ! > *--'''& 1-0 Survival analyses &' 1 ' D 1 2@ ' D 1 1 ' 1 1 ' 1! > * ( 0)! 2@ ' 1 &''1 1 ( >1 Immunohistochemistry ' 1 ! & *. 4 10 . 1 *F H 0 ' & 1 1 .& 1 8: 83 *$ 0 %( *8>0 / Downloaded from cancerres.aacrjournals.org on September 30, 2021. © 2016 American Association for Cancer Research. Author Manuscript Published OnlineFirst on May 20, 2016; DOI: 10.1158/0008-5472.CAN-15-3121 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. %$ ! @#! *.&0 #$ ' B 1 J . (/ J . ' *+9399;0. 1 ! #$ - 1!' ' C ' . 1 #$ ' . 1 ' '! #$ */0 Cell culture and reagents ! 1 /<"$-6 2 ' & . 14;!4;4 " ' (2#6+; ' ;G 4$!1 ;; -$ ;;)1-$ * 1!. 0 ' 1 Mycoplasma Retroviral transduction !18E. %$ !' &( !2( F! *0 ( ' 1 2 >1 1 ' ' 431- * 1! . 0 %$ ! ' ' B ' !%$ !* 2+,3?.&0 # !A1 1 ! #1%*N> #( $ 0 Analysis of cellular glycolysis 6 Downloaded from cancerres.aacrjournals.org on September 30, 2021. © 2016 American Association for Cancer Research. Author Manuscript Published OnlineFirst on May 20, 2016; DOI: 10.1158/0008-5472.CAN-15-3121 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. ' 1 " H,6 .D *E " . .0 !& 8 * 1!. 0 ' 4$!1 @<+ ' H,6 ! ' ! > *"8 " 0 +;+ -' ' 1 ' 1 *;/ 0 4!8%*+; 0' A Tumor therapy experiments /<"-6 1 6!3'> ' A & ' /;/ ! ' F! F!%$ !! > . : ' & ' 1 D ' ! <-6! 18E. 1 ' ' ' :!'> ' 1 *1' 4 . ' 1)@5 1 * & 22$:;-:;430 Statistical analysis 1 &' 1 ! C 1 ! > ) >!C * 1 41 0' 11 ' & ! ' M1; 1 1 1 ' 1 > ' 1 * 0 *1 0 1 1 1 ' ' > < Downloaded from cancerres.aacrjournals.org on September 30, 2021. © 2016 American Association for Cancer Research. Author Manuscript Published OnlineFirst on May 20, 2016; DOI: 10.1158/0008-5472.CAN-15-3121 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Sry The HNSC transcriptome is organized into consistent modules of coexpressed genes, which correspond to distinct biological processes 1 1 ' ' ' #$ & ' C%E. @E (E.! B *60 & & %.* 1 ' 0 D & @2F! *Q:+0 @2F! 1 *Q440 @2F! ' & 1 (E.! B @2F1 *60. ! 1 1 ' & ' &'1 +;;; 1 > & ' A C 4 1 1 ' & 1& 1 * 1.0. ' ' >& ' & ' & & --''' &- -6< DD4''+,1-.." #@,$7 )B#R Q; & ' 1 & 1 % 51 *%50 ' % * --1 1-0 . & 4 1 %51 1 > 6QR:Q 1 D R Q> R 3Q 1 ! R* & 0 . %51 & 4 3 Downloaded from cancerres.aacrjournals.org on September 30, 2021. © 2016 American Association for Cancer Research. Author Manuscript Published OnlineFirst on May 20, 2016; DOI: 10.1158/0008-5472.CAN-15-3121 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. ' >' & ' ' (E.! B ' ' @E *! ."!:;4 '''& >- ? --& >- -2& 2 A R Q:60*<305 +;;;1 ' >://<*33,G0' 1 ' > *,0 */ 1 1 Q 1 (E. & R0' 1 @E * & 0 ' 11 1 & @E > 1 / > & +3 (E.! B1 / & 1C21orf62&1 2 & @E *& 0' ' 1 *6 4; 40 &' ' %.!@E ' >* 1 "0 ' &' 1R & 1 1 ' > ' 11 @E ' 1 & * 1 !0 *:34 & 0 ' > & 1 *Q! R0 ' * 1 0 ' & 1 > ' - 1 & & ' 1 *4;0" & &' & EGFR MYC1 *40 ' HRAS-CASP8! *60 4 + * 1 80 1 , Downloaded from cancerres.aacrjournals.org on September 30, 2021. © 2016 American Association for Cancer Research. Author Manuscript Published OnlineFirst on May 20, 2016; DOI: 10.1158/0008-5472.CAN-15-3121 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. & ' ' ' ' > 1 1 ,* 10 6/ * 10 & & : , :B' @2F! >EGFR , D &*640 Coexpression modules are significantly associated with HNSC biomarkers 1 & ' D & 11*0*;0 ' 1 * 1 %0 1 1 ' >' @E & > 1 1 1 #$ B ' @2F! %(1 +*%5 > 0 ' 1 * +Q!;30 ' + 1 & ' '! > D 1 1 ! > !6"2 &' %( @2F! 1 *440 + 4*%5' 10' 1 ' EGFR1 * 4Q;66? +Q;660 ' @2F! * 4Q!;<3? +Q !;<:0 ' 1 ' #$ * Q;640 ' & 1 1 ' EGFR * Q!;//0 @2F! * Q;/:0 1 &' #$ %( ; Downloaded from cancerres.aacrjournals.org on September 30, 2021. © 2016 American Association for Cancer Research. Author Manuscript Published OnlineFirst on May 20, 2016; DOI: 10.1158/0008-5472.CAN-15-3121 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 1 &'1 ' 1 ' & D 1 *4:0 2 1 1 .
Load more

Recommended publications
  • ENSG Gene Encodes Effector TCR Pathway Costimulation Inhibitory/Exhaustion Synapse/Adhesion Chemokines/Receptors
    ENSG Gene Encodes Effector TCR pathway Costimulation Inhibitory/exhaustion Synapse/adhesion Chemokines/receptors ENSG00000111537 IFNG IFNg x ENSG00000109471 IL2 IL-2 x ENSG00000232810 TNF TNFa x ENSG00000271503 CCL5 CCL5 x x ENSG00000139187 KLRG1 Klrg1 x ENSG00000117560 FASLG Fas ligand x ENSG00000121858 TNFSF10 TRAIL x ENSG00000134545 KLRC1 Klrc1 / NKG2A x ENSG00000213809 KLRK1 Klrk1 / NKG2D x ENSG00000188389 PDCD1 PD-1 x x ENSG00000117281 CD160 CD160 x x ENSG00000134460 IL2RA IL-2 receptor x subunit alpha ENSG00000110324 IL10RA IL-10 receptor x subunit alpha ENSG00000115604 IL18R1 IL-18 receptor 1 x ENSG00000115607 IL18RAP IL-18 receptor x accessory protein ENSG00000081985 IL12RB2 IL-12 receptor x beta 2 ENSG00000186810 CXCR3 CXCR3 x x ENSG00000005844 ITGAL CD11a x ENSG00000160255 ITGB2 CD18; Integrin x x beta-2 ENSG00000156886 ITGAD CD11d x ENSG00000140678 ITGAX; CD11c x x Integrin alpha-X ENSG00000115232 ITGA4 CD49d; Integrin x x alpha-4 ENSG00000169896 ITGAM CD11b; Integrin x x alpha-M ENSG00000138378 STAT4 Stat4 x ENSG00000115415 STAT1 Stat1 x ENSG00000170581 STAT2 Stat2 x ENSG00000126561 STAT5a Stat5a x ENSG00000162434 JAK1 Jak1 x ENSG00000100453 GZMB Granzyme B x ENSG00000145649 GZMA Granzyme A x ENSG00000180644 PRF1 Perforin 1 x ENSG00000115523 GNLY Granulysin x ENSG00000100450 GZMH Granzyme H x ENSG00000113088 GZMK Granzyme K x ENSG00000057657 PRDM1 Blimp-1 x ENSG00000073861 TBX21 T-bet x ENSG00000115738 ID2 ID2 x ENSG00000176083 ZNF683 Hobit x ENSG00000137265 IRF4 Interferon x regulatory factor 4 ENSG00000140968 IRF8 Interferon
    [Show full text]
  • Screening and Identification of Key Biomarkers in Clear Cell Renal Cell Carcinoma Based on Bioinformatics Analysis
    bioRxiv preprint doi: https://doi.org/10.1101/2020.12.21.423889; this version posted December 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Screening and identification of key biomarkers in clear cell renal cell carcinoma based on bioinformatics analysis Basavaraj Vastrad1, Chanabasayya Vastrad*2 , Iranna Kotturshetti 1. Department of Biochemistry, Basaveshwar College of Pharmacy, Gadag, Karnataka 582103, India. 2. Biostatistics and Bioinformatics, Chanabasava Nilaya, Bharthinagar, Dharwad 580001, Karanataka, India. 3. Department of Ayurveda, Rajiv Gandhi Education Society`s Ayurvedic Medical College, Ron, Karnataka 562209, India. * Chanabasayya Vastrad [email protected] Ph: +919480073398 Chanabasava Nilaya, Bharthinagar, Dharwad 580001 , Karanataka, India bioRxiv preprint doi: https://doi.org/10.1101/2020.12.21.423889; this version posted December 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Clear cell renal cell carcinoma (ccRCC) is one of the most common types of malignancy of the urinary system. The pathogenesis and effective diagnosis of ccRCC have become popular topics for research in the previous decade. In the current study, an integrated bioinformatics analysis was performed to identify core genes associated in ccRCC. An expression dataset (GSE105261) was downloaded from the Gene Expression Omnibus database, and included 26 ccRCC and 9 normal kideny samples. Assessment of the microarray dataset led to the recognition of differentially expressed genes (DEGs), which was subsequently used for pathway and gene ontology (GO) enrichment analysis.
    [Show full text]
  • Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse
    Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only.
    [Show full text]
  • SUPPLEMENTARY DATA Supplementary Tables Table S1
    1 SUPPLEMENTARY DATA 2 3 Supplementary Tables 4 Table S1. Gene signatures Gene signature Genes Cytolytic GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 Cytotoxic CD8+ T cells CD8A, GZMA, GZMB, IFNG, EOMES, PRF1 Activated CD4+ T cells CD4, IL2RA, CD69 CD4+ Treg cells FOXP3, CTLA4, ICOS Immune checkpoints—T cells BTLA, LAG3, HAVCR2, PDCD1, TIGIT, CTLA4 T cells CD2, CD3D, CD3E, CD3G, CD6, TRAT1, CD28, LCK B cells CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, FCRL5 NK cells SLAMF7, KLRC3, KLRK1, KLRC2, KLRD1 Monocytes CD14, CD16, CD163, CSF1R, HLA-DR LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, M2 macrophages PTPRC, SLA, SEPSECS, MSR1, FPR3, FCGR2A, FCGR3A, IDO1, RERE, ABL2, CD163L1, STAT3, SBNO2, CSF1, CSF2 FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL12a1, Active fibroblasts COL5A1, COL8A2, THY1, PALLD Antigen processing TAPBP, TAP1, TAP2, PSMB9, PSMB8 Immune checkpoints—APC CD274, PDCD1LG2, IDO1 Costimulatory ligands CD40, CD80, CD86, CD70, TNFRSF18 CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, Costimulatory receptors TNFSF14, CD226 Myeloid inflammation CCL2, IL1B, CXCL8, IL6, PTGS2 1 DERL1, DERL2, DNAJB11, DNAJB9, DNAJC10, DNAJC3, ER stress EDEM1, EDEM2, EDEM3, EIF2AK3, ERO1L, HERPUD1, PDIA3, PDIA6, SEC61A1, SERP1, SYVN1 RRM2, UBE2C, BIRC5, CEP55, CCNB1, NUF2, NDC80, Proliferation MKI67, CDC20, TYMS 5 ER, endoplasmic reticulum; NK, natural killer. 6 7 2 8 Table S2. Most common all-cause and treatment-related AEs Patients (N = 45) All cause Treatment related Eventa Any grade Grade 3/4 Any grade Grade 3/4 Any AE 45 (100.0) 20 (44.4)
    [Show full text]
  • CD200, Human Recombinant Recombinant Human CD200, : 408-493-1800 | Fax: 408-493-1801 408-493-1801 Fax: | 408-493-1800
    BioVision 1/14 For research use only CD200, human recombinant CATALOG #: 7309-50 50 µg ALTERNATE NAMES: CD200 molecule, MOX1, MOX2, MRC, OX-2 SOURCE: E. coli PURITY: > 90% by SDS-PAGE MOL. WEIGHT: 24.8 kDa (225 aa, 31-232 aa + His tag), confirmed by MALDI-TOF. ENDOTOXIN LEVEL: < 1.0 EU per 1 µg of protein FORM: Liquid FORMULATION: 1 mg/ml in 20 mM Tris-HCl buffer (pH 8.0) containing 0.4M Urea. CD200, human recombinant STORAGE CONDITIONS: Can be stored at 4°C short term (1-2 weeks). For long term storage, aliquot and store at -20°C or - 70°C. Avoid repeated freezing and thawing RELATED PRODUCTS: cycles. • CD1E, human recombinant (Cat. No. 7308-100) • CD226, human recombinant (Cat. No. 7310-100) DESCRIPTION : CD200 is a type-1 membrane glycoprotein, which contains two • CD274, mouse recombinant (Cat. No. 7311-100) immunoglobulin domains, and thus belongs to the immunoglobulin superfamily. Studies of • CD300C, human recombinant (Cat. No. 7312-100) the related genes in mouse and rat suggest that this gene may regulate myeloid cell • CD3G, human recombinant (Cat. No. 7313-100) activity and delivers an inhibitory signal for the macrophage lineage in diverse tissues. • CD46, human recombinant (Cat. No. 7314-100) Multiple alternatively spliced transcript variants that encode different isoforms have been • CD5, human recombinant (Cat. No. 7315-100) • CD7, human recombinant (Cat. No. 7316-100) found for this gene. Recombinant human CD200 protein, fused to His-tag at N-terminus, • CD74, human recombinant (Cat. No. 7317-100) was expressed in E.coli. • CD79B, human recombinant (Cat.
    [Show full text]
  • Transcriptional Control of Tissue-Resident Memory T Cell Generation
    Transcriptional control of tissue-resident memory T cell generation Filip Cvetkovski Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Graduate School of Arts and Sciences COLUMBIA UNIVERSITY 2019 © 2019 Filip Cvetkovski All rights reserved ABSTRACT Transcriptional control of tissue-resident memory T cell generation Filip Cvetkovski Tissue-resident memory T cells (TRM) are a non-circulating subset of memory that are maintained at sites of pathogen entry and mediate optimal protection against reinfection. Lung TRM can be generated in response to respiratory infection or vaccination, however, the molecular pathways involved in CD4+TRM establishment have not been defined. Here, we performed transcriptional profiling of influenza-specific lung CD4+TRM following influenza infection to identify pathways implicated in CD4+TRM generation and homeostasis. Lung CD4+TRM displayed a unique transcriptional profile distinct from spleen memory, including up-regulation of a gene network induced by the transcription factor IRF4, a known regulator of effector T cell differentiation. In addition, the gene expression profile of lung CD4+TRM was enriched in gene sets previously described in tissue-resident regulatory T cells. Up-regulation of immunomodulatory molecules such as CTLA-4, PD-1, and ICOS, suggested a potential regulatory role for CD4+TRM in tissues. Using loss-of-function genetic experiments in mice, we demonstrate that IRF4 is required for the generation of lung-localized pathogen-specific effector CD4+T cells during acute influenza infection. Influenza-specific IRF4−/− T cells failed to fully express CD44, and maintained high levels of CD62L compared to wild type, suggesting a defect in complete differentiation into lung-tropic effector T cells.
    [Show full text]
  • Single-Cell RNA Sequencing Demonstrates the Molecular and Cellular Reprogramming of Metastatic Lung Adenocarcinoma
    ARTICLE https://doi.org/10.1038/s41467-020-16164-1 OPEN Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma Nayoung Kim 1,2,3,13, Hong Kwan Kim4,13, Kyungjong Lee 5,13, Yourae Hong 1,6, Jong Ho Cho4, Jung Won Choi7, Jung-Il Lee7, Yeon-Lim Suh8,BoMiKu9, Hye Hyeon Eum 1,2,3, Soyean Choi 1, Yoon-La Choi6,10,11, Je-Gun Joung1, Woong-Yang Park 1,2,6, Hyun Ae Jung12, Jong-Mu Sun12, Se-Hoon Lee12, ✉ ✉ Jin Seok Ahn12, Keunchil Park12, Myung-Ju Ahn 12 & Hae-Ock Lee 1,2,3,6 1234567890():,; Advanced metastatic cancer poses utmost clinical challenges and may present molecular and cellular features distinct from an early-stage cancer. Herein, we present single-cell tran- scriptome profiling of metastatic lung adenocarcinoma, the most prevalent histological lung cancer type diagnosed at stage IV in over 40% of all cases. From 208,506 cells populating the normal tissues or early to metastatic stage cancer in 44 patients, we identify a cancer cell subtype deviating from the normal differentiation trajectory and dominating the metastatic stage. In all stages, the stromal and immune cell dynamics reveal ontological and functional changes that create a pro-tumoral and immunosuppressive microenvironment. Normal resident myeloid cell populations are gradually replaced with monocyte-derived macrophages and dendritic cells, along with T-cell exhaustion. This extensive single-cell analysis enhances our understanding of molecular and cellular dynamics in metastatic lung cancer and reveals potential diagnostic and therapeutic targets in cancer-microenvironment interactions. 1 Samsung Genome Institute, Samsung Medical Center, Seoul 06351, Korea.
    [Show full text]
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • Cellular and Molecular Signatures in the Disease Tissue of Early
    Cellular and Molecular Signatures in the Disease Tissue of Early Rheumatoid Arthritis Stratify Clinical Response to csDMARD-Therapy and Predict Radiographic Progression Frances Humby1,* Myles Lewis1,* Nandhini Ramamoorthi2, Jason Hackney3, Michael Barnes1, Michele Bombardieri1, Francesca Setiadi2, Stephen Kelly1, Fabiola Bene1, Maria di Cicco1, Sudeh Riahi1, Vidalba Rocher-Ros1, Nora Ng1, Ilias Lazorou1, Rebecca E. Hands1, Desiree van der Heijde4, Robert Landewé5, Annette van der Helm-van Mil4, Alberto Cauli6, Iain B. McInnes7, Christopher D. Buckley8, Ernest Choy9, Peter Taylor10, Michael J. Townsend2 & Costantino Pitzalis1 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. Departments of 2Biomarker Discovery OMNI, 3Bioinformatics and Computational Biology, Genentech Research and Early Development, South San Francisco, California 94080 USA 4Department of Rheumatology, Leiden University Medical Center, The Netherlands 5Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands 6Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Cagliari, Italy 7Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK 8Rheumatology Research Group, Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham B15 2WB, UK 9Institute of
    [Show full text]
  • Mutational Landscape Differences Between Young-Onset and Older-Onset Breast Cancer Patients Nicole E
    Mealey et al. BMC Cancer (2020) 20:212 https://doi.org/10.1186/s12885-020-6684-z RESEARCH ARTICLE Open Access Mutational landscape differences between young-onset and older-onset breast cancer patients Nicole E. Mealey1 , Dylan E. O’Sullivan2 , Joy Pader3 , Yibing Ruan3 , Edwin Wang4 , May Lynn Quan1,5,6 and Darren R. Brenner1,3,5* Abstract Background: The incidence of breast cancer among young women (aged ≤40 years) has increased in North America and Europe. Fewer than 10% of cases among young women are attributable to inherited BRCA1 or BRCA2 mutations, suggesting an important role for somatic mutations. This study investigated genomic differences between young- and older-onset breast tumours. Methods: In this study we characterized the mutational landscape of 89 young-onset breast tumours (≤40 years) and examined differences with 949 older-onset tumours (> 40 years) using data from The Cancer Genome Atlas. We examined mutated genes, mutational load, and types of mutations. We used complementary R packages “deconstructSigs” and “SomaticSignatures” to extract mutational signatures. A recursively partitioned mixture model was used to identify whether combinations of mutational signatures were related to age of onset. Results: Older patients had a higher proportion of mutations in PIK3CA, CDH1, and MAP3K1 genes, while young- onset patients had a higher proportion of mutations in GATA3 and CTNNB1. Mutational load was lower for young- onset tumours, and a higher proportion of these mutations were C > A mutations, but a lower proportion were C > T mutations compared to older-onset tumours. The most common mutational signatures identified in both age groups were signatures 1 and 3 from the COSMIC database.
    [Show full text]
  • FOR RESEARCH USE ONLY 03/08V1 Recombinant Human
    Recombinant Human CD3G Datasheet Catalog Number: PR27294 Product Type: Recombinant Protein Source: Sf9, Insect Cells Amino Acid Sequence: ADPQSIKGNH LVKVYDYQED GSVLLTCDAE AKNITWFKDG KMIGFLTEDK KKWNLGSNAK DPRGMYQCKG SQNKSKPLQV YYRMCQNCIE LNAATISHHH HHH. Description/Molecular CD3-gamma polypeptide is encoded by CD3 Gamma (CD3G) which together with CD3-epsilon, -delta Mass: and -zeta, and the T-cell receptor alpha/beta and gamma/delta heterodimers, configures the T-cell receptor-CD3 complex. The T-cell receptor-CD3 complex takes part in coupling antigen recognition to numerous intracellular signal-transduction pathways. The genes encoding the epsilon, gamma and delta polypeptides are located in the same cluster on chromosome 11. Deficiencies in this gene are associated with T cell immunodeficiency. CD3G Human Recombinant produced in Sf9 Insect cells is a single, glycosylated polypeptide chain containing 103 amino acids (23-116 a.a.) and having a molecular mass of 11.8kDa (Molecular size on SDS-PAGE will appear at approximately 13.5-18kDa). CD3G is expressed with a 6 amino acids His tag at C-Terminus and purified by proprietary chromatographic techniques. Purity: Greater than 90.0% as determined by: (a) Analysis by SDS-PAGE. Format: CD3G protein solution (0.5mg/ml) contains phosphate buffered saline (pH7.4) and 10% glycerol. Storage: Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time. For long term storage, it is recommended to add a carrier protein (0.1% HSA or BSA). Avoid multiple freeze-thaw cycles. FOR RESEARCH USE ONLY NEUROMICS’ REAGENTS ARE FOR IN VITRO AND CERTAIN NON-HUMAN IN VIVO EXPERIMENTAL USE ONLY AND NOT INTENDED FOR USE IN ANY HUMAN CLINICAL INVESTIGATION, DIAGNOSIS, PROGNOSIS, OR TREATMENT.
    [Show full text]
  • Ncounter Fibrosis Panel
    PRODUCT BULLETIN nCounter® Fibrosis Panel Gene Expression Panel Four Stages of Fibrosis • Disease Pathogenesis • Biomarkers of Progression Uncover the mechanisms of disease pathogenesis, identify biomarkers of progression, and develop signatures for therapeutic response with the nCounter Fibrosis Panel. This gene expression panel combines hundreds of genes involved in the initial tissue damage response, chronic inflammation, proliferation of pro-fibrotic cells, and tissue modification that leads to fibrotic disease of the lungs, heart, liver, kidney, and skin. INITIATION Product Highlights • Profile 770 genes across 51 annotated pathways involved in the four stages of fibrosis T is s s • Initiation s u e e r I • t D N Inflammation N S a F l m • Proliferation O l L I e a A g • Modification T C M e A M C • I Study pathogenesis and identify biomarkers for fibrotic A F I T diseases of the lungs, heart, liver, kidney, and skin I D O O N • Understand the signaling cascade from cell M stress to inflammation • Quantify the relative abundance of 14 different W g ound Healin immune cell types • Identify biomarkers of therapeutic response PR N OLIFERATIO Feature Specifications Number of Targets 770 (Human), 770 (Mouse), including internal reference genes Standard Input Material (No amplification required) 25-300 ng Sample Input - Low Input As little as 1 ng with nCounter Low Input Kit (sold separately) Cultured cells/cell lysates, sorted cells, FFPE-derived RNA, total RNA, Sample Type(s) fragmented RNA, PBMCs, and whole blood/plasma Add up to 55 unique genes with Panel-Plus and up to 10 custom Customizable protein targets Time to Results Approximately 24 hours Data Analysis nSolver™ Analysis Software (RUO) FOR RESEARCH USE ONLY.
    [Show full text]